By efrat|2024-03-10T07:00:13+00:00March 10th, 2024|All|Comments Off on March 11th 2024- Dr. Adi Zoref Lorenz – Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Sweden: Incidence, Clinical Characteristics, and Survival
By efrat|2024-03-04T08:22:05+00:00March 5th, 2024|All|Comments Off on March 6th 2024- Prof. Katy Rezvani – Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19+ B Cell Tumors: a Phase 1/2 Trial
By efrat|2024-02-25T08:13:18+00:00February 24th, 2024|All|Comments Off on Feb 26th 2024- Prof. Marion Subklewe- Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
By efrat|2024-02-22T09:21:29+00:00February 21st, 2024|All|Comments Off on Feb 23rd 2024- Guido Ghilardi & Marco Ruella- T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy
By efrat|2024-02-11T09:53:40+00:00February 13th, 2024|All|Comments Off on Feb 14th 2024- Dr. Joshua Fein- Simple Score of Albumin and CRP Predicts High Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
By efrat|2024-02-04T08:04:14+00:00February 4th, 2024|All|Comments Off on Feb 5th 2024- Prof. Ali Bazarbachi- Sorafenib Plus Intensive Chemotherapy in Newly Diagnosed FLT3-ITD AML: A Randomized, Placebo-Controlled Study by the ALLG
By efrat|2024-02-02T07:23:05+00:00February 2nd, 2024|All|Comments Off on Feb 2nd 2024- Dr. Paula Rodriguez-Otero- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization approval for idecabtagene vicleucel (Abecma; ide-cel) for use in adult patients with relapsed and refractory multiple myeloma who previously received at least 2 therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody
By efrat|2024-01-21T08:20:40+00:00January 22nd, 2024|All|Comments Off on Jan 23rd 2024- Prof. Daniel Wolff- Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with CGVHD Disease (AGAVE-201)
By efrat|2024-01-07T07:28:24+00:00January 6th, 2024|All|Comments Off on Jan 8th 2024- David Valcarcel & Adrian Mosquera- Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
By efrat|2023-12-13T10:37:16+00:00December 18th, 2023|All|Comments Off on Dec 19th 2023- Prof. Florent Malard- Gut Microbiota Diversity Before Allogeneic Hematopoietic Stem Cell Transplantation as a Predictor of Mortality in Children
